Transcatheter or surgical aortic-valve replacement in intermediate-risk patients

Authors: Leon, Martin B; Smith, Craig R.; Mack, Michael J.; Makkar, Rajendra; Svensson, Lars G.; Kodali, Susheel; Thourani, Vinod H.; Tuzcu, Murat; Miller, D. Craig; Herrmann, Howard C.; Doshi, Darshan; Cohen, David J.; Pichard, Augusto D.; Kapadia, Samir R.; Dewey, Todd; Babaliaros, Vasilis; Szeto, Wilson Y.; Williams, Mathew; Kereiakes, Dean J.; Zajarias, Alan; Greason, Kevin L.; Whisenant, Brian K.; Hodson, Robert W.; Moses, Jeffrey W.; Trento, Alfredo; Brown, David L.; Fearon, William F.; Pibarot, Philippe; Hahn, Rebecca T.; Jaber, Wael A.; Anderson, William N.; Alu, Maria C.; Webb, John G.
Abstract: BACKGROUND: Previous trials have shown that among high-risk patients with aortic stenosis, survival rates are similar with transcatheter aortic-valve replacement (TAVR) and surgical aorticvalve replacement. We evaluated the two procedures in a randomized trial involving intermediate-risk patients. METHODS: We randomly assigned 2032 intermediate-risk patients with severe aortic stenosis, at 57 centers, to undergo either TAVR or surgical replacement. The primary end point was death from any cause or disabling stroke at 2 years. The primary hypothesis was that TAVR would not be inferior to surgical replacement. Before randomization, patients were entered into one of two cohorts on the basis of clinical and imaging findings; 76.3% of the patients were included in the transfemoral-access cohort and 23.7% in the transthoracic-access cohort. RESULTS: The rate of death from any cause or disabling stroke was similar in the TAVR group and the surgery group (P=0.001 for noninferiority). At 2 years, the Kaplan–Meier event rates were 19.3% in the TAVR group and 21.1% in the surgery group (hazard ratio in the TAVR group, 0.89; 95% confidence interval [CI], 0.73 to 1.09; P=0.25). In the transfemoralaccess cohort, TAVR resulted in a lower rate of death or disabling stroke than surgery (hazard ratio, 0.79; 95% CI, 0.62 to 1.00; P=0.05), whereas in the transthoracic-access cohort, outcomes were similar in the two groups. TAVR resulted in larger aortic-valve areas than did surgery and also resulted in lower rates of acute kidney injury, severe bleeding, and new-onset atrial fibrillation; surgery resulted in fewer major vascular complications and less paravalvular aortic regurgitation. CONCLUSIONS: In intermediate-risk patients, TAVR was similar to surgical aortic-valve replacement with respect to the primary end point of death or disabling stroke. (Funded by Edwards Lifesciences; PARTNER 2 ClinicalTrials.gov number, NCT01314313.
Document Type: Article de recherche
Issue Date: 2 April 2016
Open Access Date: 2 October 2016
Document version: VoR
Permalink: http://hdl.handle.net/20.500.11794/6713
This document was published in: The New England Journal of Medicine, Vol. 374 (17), 1609–1620 (2016)
https://doi.org/10.1056/NEJMoa1514616
Massachusetts Medical Society
Alternative version: 10.1056/NEJMoa1514616
27040324
Collection:Articles publiés dans des revues avec comité de lecture

Files in this item:
SizeFormat 
Leon2016-15140.pdf526.64 kBAdobe PDFView/Open
All documents in CorpusUL are protected by Copyright Act of Canada.